TRG035 tooth-regrowth drug: trial status, eligibility and availability

TRG035 is an investigational tooth-regeneration drug candidate, not an established replacement for a dental implant. Its developer, Toregem, announced on August 17, 2026 that the required Japanese review of a clinical-trial notification for an exploratory Phase IIa study had been completed. The intended condition was congenital tooth agenesis. The announcement was a trial-development update, not a published efficacy result. 1

This report uses the developer's announcement for that event and Kitano Hospital's historical first-in-human plan for the earlier stage. It does not infer completed patient outcomes from the passage of time.

What is TRG035?

Toregem describes an antibody approach directed at USAG-1, a regulator involved in tooth development. The program aims to change developmental signaling rather than insert a replacement tooth. Its first intended application and its ambition to expand into acquired tooth loss are distinct. 2

The USAG-1 explainer explains the difference between targeting a developmental mechanism and demonstrating a functioning new tooth in a particular patient population.

The documented timeline

The earlier hospital plan described IACT21031 as a single-dose, randomized, placebo-controlled dose-escalation study focused on safety and dose selection. It referred to healthy men aged 30–65 with at least one missing molar and said the first-in-human study was not generally recruiting patients. These are historical protocol details, not current recruitment criteria. 3

The timeline is useful precisely because it does not quietly transform a plan into a result. A study can have a planned completion date without that date supplying its findings.

Who might the research eventually help?

The initial disease target is congenital tooth agenesis. That means the trial question should not be restated as “does it replace every adult tooth lost to decay, injury or gum disease?” The developer discusses broader acquired tooth loss as an ambition, not an established indication. 2

There is also a difference between a development population and an individual eligibility decision. The earlier safety cohort does not provide a universal enrollment checklist for a later efficacy study. The correct patient group depends on the actual protocol, not on combining ages or inclusion criteria from different announcements.

We therefore do not publish a “sign up here to regrow your teeth” form. This publication has no allocation of trial places and does not collect medical records to claim eligibility.

What results have been established by the August notice?

The notice establishes an administrative clinical-development event. It does not contain a results table showing how many people grew teeth, a comparison against placebo, a full adverse-event analysis, or a demonstration that new teeth were durable and functional. 1

Those omissions do not show that the approach failed. They show that this particular document is not the document from which to calculate a human treatment success rate. The difference matters: neither optimism nor skepticism should supply results that have not been reported in the source.

For a future efficacy report, the most useful denominator would be all relevant treated or randomized participants under the stated analysis—not only photographs of successful cases. A defensible account would also explain what counted as tooth development and the duration of follow-up.

Is TRG035 available, and how much does it cost?

An approved public treatment price and launch date are not established by the records used here. The Phase IIa announcement is not a marketing authorization. We have not verified routine retail availability. 1

A price quoted for implants, dental travel or an unrelated “regenerative” service cannot be substituted for an approved TRG035 price. Nor does a provider's use of the word regeneration show that it supplies this antibody candidate.

For context, the implant comparison explains why a present-day replacement and a possible future biological treatment cannot yet be compared as two equivalent purchasable products.

What the next update needs to answer

The next consequential evidence would be a clearly identified human study report: population, intervention, comparison, outcome definition, observation period and harms. A later trial notification would update the development pathway; a positive efficacy result would answer a different question; authorization would answer another.

Keeping those events separate lets this page remain useful when the program changes. Its present conclusion is specific: TRG035 has a documented clinical-development pathway, but the cited 2026 milestone is not evidence that a commercially available drug now regrows ordinary lost adult teeth.